MERCK KGAA

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1668-01-01

Employees: 62.9K

Market Cap: $84.2B

Website: http://www.merckgroup.com/de

Clinical Trials

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects

Phase 3

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Biological: Cetuximab + concomitant boost radiotherapy

First Posted Date: 2009-11-13

Last Posted Date: 2015-07-09

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 70

Registration Number: NCT01012258

Locations: 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

and more 5 locations

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: EMD 640744
Other: Montanide ISA 51 VG

First Posted Date: 2009-11-11

Last Posted Date: 2014-02-20

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 104

Registration Number: NCT01012102

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: EMD 525797 250 mg
Drug: EMD 525797 500 mg
Drug: EMD 525797 750 mg
Drug: EMD 525797 1000 mg
Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2009-11-05

Last Posted Date: 2016-03-30

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 232

Registration Number: NCT01008475

Locations: 🇬🇧
Research Site, Sutton, United Kingdom
🇷🇺
Research, Arkhangelsk, Russian Federation
🇩🇪
Research site, Hannover, Germany

Trial of MSC1936369B in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors
Cancer

Interventions: Drug: MSC1936369B

First Posted Date: 2009-09-23

Last Posted Date: 2018-10-23

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 182

Registration Number: NCT00982865

Locations: 🇫🇷
Hopital Saint Louis, Paris, France
🇦🇺
Westmead Hospital, Westmead, Australia
🇫🇷
Centre Eugène Marquis, Rennes, France

and more 6 locations

Raptiva in Palm and Sole Psoriasis

Phase 4

Terminated

Conditions: Chronic Plaque Psoriasis

Interventions: Biological: Efalizumab (Raptiva)
Biological: Placebo

First Posted Date: 2009-09-07

Last Posted Date: 2014-02-13

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 6

Registration Number: NCT00972543

Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Cetuximab
Drug: Cisplatin/Carboplatin
Drug: 5-Fluorouracil

First Posted Date: 2009-09-04

Last Posted Date: 2014-04-08

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 33

Registration Number: NCT00971932

Locations: 🇯🇵
Research Site, Tokyo, Japan
🇯🇵
Tokai University, Kanagawa, Japan
🇯🇵
National Cancer Center East Hospital, Chiba, Japan

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Tecemotide (L-BLP25)
Biological: Placebo
Other: Saline
Drug: Single low dose cyclophosphamide

First Posted Date: 2009-08-17

Last Posted Date: 2015-10-21

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 178

Registration Number: NCT00960115

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer
Bone Metastases

Interventions: Biological: EMD 525797

First Posted Date: 2009-08-13

Last Posted Date: 2017-08-02

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 26

Registration Number: NCT00958477

Locations: 🇧🇪
Institut Jules Bordet - Medical Oncology Clinic, Brussels, Belgium
🇩🇪
Universitätsklinikum Aachen, AÖR - Medizinische Fakultät der RWTH - Klinik für Urologie, Aachen, Germany
🇩🇪
Klinikum Rechts der Isar - Urologische Klinik und Poliklinik, München, Germany

and more 1 locations

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Cladribine
Drug: Pantoprazole

First Posted Date: 2009-07-13

Last Posted Date: 2016-04-14

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 18

Registration Number: NCT00938366

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Phase 3

Completed

Conditions: Fibromyalgia

Interventions: Drug: Saizen®
Drug: Placebo and Saizen®

First Posted Date: 2009-07-07

Last Posted Date: 2013-08-02

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 113

Registration Number: NCT00933686

Locations: 🇪🇸
Centro Medico Teknon, Endocrinology Department, Barcelona, Spain

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy